E Fund Management Co. Ltd. Acquires Shares of 39,494 ImmunityBio, Inc. (NASDAQ:IBRX)

E Fund Management Co. Ltd. acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 39,494 shares of the company’s stock, valued at approximately $198,000.

Other large investors also recently added to or reduced their stakes in the company. Clearwater Capital Advisors LLC boosted its stake in ImmunityBio by 12.3% in the 4th quarter. Clearwater Capital Advisors LLC now owns 443,299 shares of the company’s stock worth $2,225,000 after purchasing an additional 48,700 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of ImmunityBio by 8.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,142,925 shares of the company’s stock worth $5,737,000 after purchasing an additional 92,991 shares during the period. Private Advisor Group LLC purchased a new stake in shares of ImmunityBio in the fourth quarter worth $53,000. Amalgamated Bank grew its position in ImmunityBio by 21.9% during the fourth quarter. Amalgamated Bank now owns 17,752 shares of the company’s stock worth $89,000 after buying an additional 3,186 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in ImmunityBio by 25.8% in the 4th quarter. Victory Capital Management Inc. now owns 17,642 shares of the company’s stock worth $89,000 after acquiring an additional 3,613 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $7.96 on Friday. ImmunityBio, Inc. has a one year low of $1.25 and a one year high of $10.53. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of -6.95 and a beta of 1.16. The company’s fifty day moving average price is $5.94 and its 200-day moving average price is $4.63.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Tuesday, March 19th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.03 million. As a group, equities research analysts expect that ImmunityBio, Inc. will post -0.76 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler lifted their price target on ImmunityBio from $5.00 to $6.00 and gave the company a “neutral” rating in a research report on Monday, April 29th.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.